Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by Citizens Jmp

Citizens Jmp upgraded shares of Sana Biotechnology (NASDAQ:SANA - Free Report) from a market perform rating to an outperform rating in a research note published on Tuesday, Marketbeat reports. They currently have $5.00 price target on the stock.

A number of other analysts have also recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They set a "buy" rating and a $7.00 target price for the company. HC Wainwright boosted their target price on shares of Sana Biotechnology from $8.00 to $11.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Finally, TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $10.80.

Sana Biotechnology Stock Performance

Shares of SANA stock traded up $0.05 on Tuesday, reaching $2.31. 4,923,605 shares of the company were exchanged, compared to its average volume of 3,051,681. The company has a market cap of $519.81 million, a price-to-earnings ratio of -1.65 and a beta of 1.63. The business has a 50-day moving average price of $2.95 and a 200 day moving average price of $3.16. Sana Biotechnology has a 1 year low of $1.52 and a 1 year high of $10.50.

Remove Ads

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Monday, March 17th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. As a group, equities analysts anticipate that Sana Biotechnology will post -1.16 earnings per share for the current year.

Insider Buying and Selling

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the business's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the transaction, the insider now directly owns 4,541,511 shares in the company, valued at $29,474,406.39. The trade was a 6.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 31.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of SANA. Cerity Partners LLC acquired a new position in Sana Biotechnology in the 4th quarter valued at about $25,000. Tower Research Capital LLC TRC boosted its holdings in Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after purchasing an additional 10,548 shares during the last quarter. Syon Capital LLC acquired a new position in Sana Biotechnology in the 4th quarter valued at about $27,000. Wilmington Savings Fund Society FSB acquired a new position in Sana Biotechnology in the 3rd quarter valued at about $29,000. Finally, Ameriprise Financial Inc. acquired a new position in Sana Biotechnology in the 4th quarter valued at about $29,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.